Cotinine replacement levels for a 21 mg/day transdermal nicotine patch in an outpatient treatment setting

被引:9
作者
Gariti, P [1 ]
Alterman, AI
Barber, W
Bedi, N
Luck, G
Cnaan, A
机构
[1] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[2] VA Med Ctr, Philadelphia, PA USA
关键词
smokers; cotinine replacement; patch treatment;
D O I
10.1016/S0376-8716(98)00163-X
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This study examined plasma cotinine replacement levels of 56 outpatient smokers administered a 21 mg/day transdermal nicotine patch (Nicoderm CQ(R)). The percentage of cotinine replacement ranged from 35 to 232% (mean 107%; median 90.5%). Four subject variables were found to be significantly correlated with percentage of cotinine replacement-baseline cotinine level, prior quit attempts, gender, and the Fagerstrom Tolerance Questionnaire score. A two-variable model consisting of baseline cotinine level and gender provided the most powerful predictor combination. The percentage of cotinine replacement was not predictive of post-treatment smoking. The relatively high levels of cotinine replacement obtained using the Nicoderm CQ(R) 21 mg/day patch suggest cautious use of higher dose treatment with this particular patch. (C) 1999 Published by Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 26 条
[1]  
BENOWITZ NL, 1986, RES ADV ALCOHOL DRUG, V9, P1
[2]   Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking [J].
Benowitz, NL ;
Zevin, S ;
Jacob, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (03) :259-267
[3]  
BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318
[4]   HIGH-DOSE NICOTINE PATCH THERAPY - PERCENTAGE OF REPLACEMENT AND SMOKING CESSATION [J].
DALE, LC ;
HURT, RD ;
OFFORD, KP ;
LAWSON, GM ;
CROGHAN, IT ;
SCHROEDER, DR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (17) :1353-1358
[5]   RELIABILITY AND VALIDITY OF 6-MONTH TIMELINE REPORTS OF COCAINE AND HEROIN USE IN A METHADONE POPULATION [J].
EHRMAN, RN ;
ROBBINS, SJ .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1994, 62 (04) :843-850
[7]  
FAGERSTROM KO, 1994, J SMOK RELAT DISORD, V5, P179
[8]   HIGH-DOSE TRANSDERMAL NICOTINE THERAPY FOR HEAVY SMOKERS - SAFETY, TOLERABILITY AND MEASUREMENT OF NICOTINE AND COTININE LEVELS [J].
FREDRICKSON, PA ;
HURT, RD ;
LEE, GM ;
WINGENDER, L ;
CROGHAN, IT ;
LAUGER, G ;
GOMEZDAHL, L ;
OFFORD, KP .
PSYCHOPHARMACOLOGY, 1995, 122 (03) :215-222
[9]   STEADY-STATE PHARMACOKINETICS AND DOSE RELATIONSHIP OF NICOTINE DELIVERED FROM NICODERM(R) (NICOTINE TRANSDERMAL SYSTEM) [J].
GORSLINE, J ;
GUPTA, SK ;
DYE, D ;
ROLF, CN .
JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (02) :161-168
[10]   BIOAVAILABILITY AND ABSORPTION KINETICS OF NICOTINE FOLLOWING APPLICATION OF A TRANSDERMAL SYSTEM [J].
GUPTA, SK ;
BENOWITZ, NL ;
JACOB, P ;
ROLF, CN ;
GORSLINE, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (03) :221-227